Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Research dashboard

Search approved medicines for AI-predicted activity against four drug-resistant pathogens, and see what evidence is already documented for each one.

TryTuberculosisMRSAKlebsiella infectionE. coli infection

1,761

Approved medicines

Approved medicines matched to the FDA Orange Book, antimicrobials included

1,276

Medicines with ≥40% AI-predicted activity

Against at least one of the four supported pathogens; each medicine counted once

1,019

Repurposing candidates

Of those, the medicines that are not already antimicrobials

How the repurposing candidates are counted

  1. 1,761approved medicines

  2. 1,276with AI-predicted activity ≥40% against at least one pathogen

    − 485 below ≥40%, not counted

  3. 1,120not already antimicrobials

    − 156 already antimicrobials, set aside

  4. 1,019repurposing candidates

    − 101 needing review, kept in the library

Existing antimicrobials are identified from WHO ATC codes and FDA pharmacologic classes. Medicines needing review (neither source says whether they are antimicrobials) stay in the approved-medicine download, marked “unclassified”. They are not assumed to be non-antimicrobials, so they are not counted as candidates.

Downloads

Download approved medicines (CSV)1,761 rowsDownload repurposing candidates (CSV)1,019 rows

Pathogen coverage

A medicine can count under more than one

Registered studies

A registration describes a study; it does not establish a positive result.

Condition
When these studies started38,873 of 39,548 have a start date · most in 2021 (1,903)
193119812030

  • Gradual Tapering or Discontinuation of Beta-Blockers After Stabilization With Mavacamten Therapy

    NCT07815301 · start 2026-12

    Registered record
    Registry ID
    NCT07815301
    Conditions
    Obstructive Hypertrophic Cardiomyopathy (oHCM)
    Interventions
    Beta-Blocker Sequential Tapering and Discontinuation; Beta-Blocker Baseline Stable-Dose Maintenance
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-12
    Completion
    2028-12
    Enrolment
    286

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionObstructive Hypertrophic Cardiomyopathy (oHCM)
    InterventionBeta-Blocker Sequential Tapering and Discontinuation; Beta-Blocker Baseline Stable-Dose Maintenance
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Modified FOLFIRINOX and Pentamidine in Advanced and Metastatic Pancreatic Cancer

    NCT07829185 · start 2026-12

    Registered record
    Registry ID
    NCT07829185
    Conditions
    Pancreatic Ductal Adenocarcinoma (PDAC)
    Interventions
    modified FOLFIRINOX; Pentamidine 300 MG Injection
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2026-12
    Completion
    2030-12
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPancreatic Ductal Adenocarcinoma (PDAC)
    Interventionmodified FOLFIRINOX; Pentamidine 300 MG Injection
    PhasePhase 1
    Registry statusNot yet recruiting

  • Efficacy and Safety of Cryotherapy Followed by Tirbanibulin Ointment for Actinic Keratosis on the Scalp and Forehead

    NCT07273656 · start 2026-11-30

    Registered record
    Registry ID
    NCT07273656
    Conditions
    Keratosis; Actinic Keratoses
    Interventions
    Cryotherapy + Tirbanibulin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-11-30
    Completion
    2028-11-30
    Enrolment
    59

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKeratosis; Actinic Keratoses
    InterventionCryotherapy + Tirbanibulin
    PhasePhase 3
    Registry statusNot yet recruiting

  • A Study of Lurbinectedin in Combination With Durvalumab for the Treatment of Participants With ES-SCLC

    NCT07459634 · start 2026-11-30

    Registered record
    Registry ID
    NCT07459634
    Conditions
    Extensive-stage Small-cell Lung Cancer
    Interventions
    Lurbinectedin; Durvalumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2026-11-30
    Completion
    2028-04-30
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionExtensive-stage Small-cell Lung Cancer
    InterventionLurbinectedin; Durvalumab
    PhasePhase 2
    Registry statusRecruiting

  • Comparison of Serratus Posterior Superior Intercostal Plane Block and Deep Serratus Anterior Plane Block After Video-Assisted Thoracoscopic Surgery

    NCT07553195 · start 2026-11-30

    Registered record
    Registry ID
    NCT07553195
    Conditions
    Postoperative Pain; Video Assisted Thoracic Surgery (VATS); Serratus Posterior Superior Intercostal Plane Block; Deep Serratus Anterior Plane Block
    Interventions
    Serratus Posterior Superior Intercostal Plane (SPSIP) block; Deep Serratus Anterior Plane Block (Deep SAP)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-11-30
    Completion
    2028-04-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostoperative Pain; Video Assisted Thoracic Surgery (VATS); Serratus Posterior Superior Intercostal Plane Block; Deep Serratus Anterior Plane Block
    InterventionSerratus Posterior Superior Intercostal Plane (SPSIP) block; Deep Serratus Anterior Plane Block (Deep SAP)
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Evaluation of 18F-Fluciclovine Positron Emission Tomography - Magnetic Resonance Imaging (PET-MRI) in LGG

    NCT05555550 · start 2026-11-29

    Registered record
    Registry ID
    NCT05555550
    Conditions
    Glioma; Low-grade Glioma; Low Grade Glioma of Brain; Glioma, Malignant; Glioma Intracranial
    Interventions
    18F-Fluciclovine
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Recruiting
    Start
    2026-11-29
    Completion
    2028-09
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGlioma; Low-grade Glioma; Low Grade Glioma of Brain; Glioma, Malignant +1 more
    Intervention18F-Fluciclovine
    PhaseEarly phase 1
    Registry statusRecruiting

  • Testing the Use of an IDH1 Inhibitor, Olutasidenib, in Acute Myeloid Leukemia Added to ASTX727 and Venetoclax; in High-Risk MDS Added to ASTX727; and Alone in Low Risk MDS (A MyeloMATCH Treatment Substudy)

    NCT07153497 · start 2026-11-27

    Registered record
    Registry ID
    NCT07153497
    Conditions
    Acute Myeloid Leukemia; Myelodysplastic Syndrome
    Interventions
    Biospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Decitabine and Cedazuridine; Olutasidenib; Venetoclax
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-11-27
    Completion
    2030-04-26
    Enrolment
    132

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia; Myelodysplastic Syndrome
    InterventionBiospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Decitabine and Cedazuridine +2 more
    PhasePhase 2
    Registry statusNot yet recruiting

  • A Study of Belzutifan in Adolescent Participants With Solid Tumors (MK-9999-01E/LIGHTBEAM-U01)

    NCT07700758 · start 2026-11-23

    Registered record
    Registry ID
    NCT07700758
    Conditions
    Malignant Neoplasm
    Interventions
    Belzutifan
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-11-23
    Completion
    2034-01-02
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalignant Neoplasm
    InterventionBelzutifan
    PhasePhase 2
    Registry statusNot yet recruiting

  • A Study to Learn About the Safety of Diroximel Fumarate (DRF) and Dimethyl Fumarate (DMF) and Their Effects on Relapses in Pediatric Participants With Relapsing Forms of Multiple Sclerosis (RMS)

    NCT07483632 · start 2026-11-16

    Registered record
    Registry ID
    NCT07483632
    Conditions
    Relapsing Forms of Multiple Sclerosis
    Interventions
    Diroximel Fumarate; Dimethyl Fumarate; Fingolimod; Placebo matching DRF; Placebo matching DMF; Placebo matching fingolimod
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-11-16
    Completion
    2035-06-19
    Enrolment
    185

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsing Forms of Multiple Sclerosis
    InterventionDiroximel Fumarate; Dimethyl Fumarate; Fingolimod; Placebo matching DRF +2 more
    PhasePhase 3
    Registry statusNot yet recruiting

  • Minoxidil With or Without Low-Level Red-Light Therapy for Improving Chemotherapy-Induced Alopecia in Breast Cancer Patients

    NCT07594678 · start 2026-11-15

    Registered record
    Registry ID
    NCT07594678
    Conditions
    Anatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8; Chemotherapy-Induced Alopecia
    Interventions
    Electronic Health Record Review; Minoxidil; Revian RED LED-light cap; Survey Administration
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-11-15
    Completion
    2027-12-31
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnatomic Stage I Breast Cancer AJCC v8; Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; Anatomic Stage IV Breast Cancer AJCC v8 +1 more
    InterventionElectronic Health Record Review; Minoxidil; Revian RED LED-light cap; Survey Administration
    PhasePhase 2
    Registry statusNot yet recruiting

  • Effect of Theravex Tissue Care on Implant Stability

    NCT07707388 · start 2026-11-12

    Registered record
    Registry ID
    NCT07707388
    Conditions
    Immediate Dental Implant Placement
    Interventions
    Bone Bioactive Liquid; Bovine-derived Xenograft; Immediate Implant Placement
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-11-12
    Completion
    2027-09-08
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionImmediate Dental Implant Placement
    InterventionBone Bioactive Liquid; Bovine-derived Xenograft; Immediate Implant Placement
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Efficacy and Safety of Emodepside in Participants With Soil-transmitted Helminth Infections

    NCT06800248 · start 2026-11-06

    Registered record
    Registry ID
    NCT06800248
    Conditions
    Trichuris Trichiura; Infection; Hookworm Infection; Ascaris Lumbricoides Infection
    Interventions
    emodepside (BAY 44-4400); Mebendazole 100 MG; similar placebo to mebendazole; matching placebo of emodepside
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-11-06
    Completion
    2027-10
    Enrolment
    315

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTrichuris Trichiura; Infection; Hookworm Infection; Ascaris Lumbricoides Infection
    Interventionemodepside (BAY 44-4400); Mebendazole 100 MG; similar placebo to mebendazole; matching placebo of emodepside
    PhasePhase 3
    Registry statusNot yet recruiting

  • Digital Treatment for Chronic Pain and Addiction in Veterans With Opioid Use Disorder Receiving Buprenorphine

    NCT07361432 · start 2026-11-02

    Registered record
    Registry ID
    NCT07361432
    Conditions
    Opioid Use Disorder; Chronic Pain
    Interventions
    Integrating the Management of Pain and Addiction via Collaborative Treatment (IMPACT); Enhanced Treatment as Usual (ETAU)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2026-11-02
    Completion
    2030-05-31
    Enrolment
    250

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpioid Use Disorder; Chronic Pain
    InterventionIntegrating the Management of Pain and Addiction via Collaborative Treatment (IMPACT); Enhanced Treatment as Usual (ETAU)
    PhasePhase 3
    Registry statusNot yet recruiting

  • Safety, Tolerability, and Efficacy of PLX-200 in Patients With CLN3

    NCT04637282 · start 2026-11-01

    Registered record
    Registry ID
    NCT04637282
    Conditions
    Juvenile Neuronal Ceroid Lipofuscinosis
    Interventions
    PLX-200; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Withdrawn
    Start
    2026-11-01
    Completion
    2026-12-31
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionJuvenile Neuronal Ceroid Lipofuscinosis
    InterventionPLX-200; Placebo
    PhasePhase 3
    Registry statusWithdrawn

  • Efficacy of Essential Phospholipid Versus Betaine HCL/L-Glutamic Acid in MAFLD

    NCT07194863 · start 2026-11-01

    Registered record
    Registry ID
    NCT07194863
    Conditions
    Essential Phospholipid in Metabolic Associated Fatty Liver Disease
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-11-01
    Completion
    2027-09-01
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Phospholipid in Metabolic Associated Fatty Liver Disease
    InterventionNot recorded
    PhaseNot recorded
    Registry statusNot yet recruiting

AI-predicted activity is a model’s estimate that a molecule is active against a pathogen in the laboratory. It is not clinical effectiveness. The models describe each pathogen species; the data behind them rarely records resistant strains.